Lyudmila A. Bazhenova, MD, explains the impact of having larotrectinib results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer Singapore.
Lyudmila A. Bazhenova, MD, medical oncologist and professor of Medicine at the University of California San Diego, explains the impact of having larotrectinib (Vitrakvi) results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer (WCLC) Singapore.
Prior to WCLC, the data available for larotrectinib covered solid tumors generally, Bazhenova explains. Despite not having results from a lung cancer cohort, the larotrectinib data were convincing and the drug has been widely used for the treatment of TRK fusion-positive solid tumors. Bazhenova says the efficacy of the drug appears to be similar across all solid tumor types.
The key benefit of now having around larotrectinib specifically in the TRK fusion-positive lung cancer population is that oncologists can tell their patients what to expect with the drug, Bazhenova explains. According to the data, patients can achieve a response rate of up to 77%.